Form 4: Incyte Director Otis Brawley Reports Significant Equity Compensation Awards

Incyte Corporation Director Otis W. Brawley reported the acquisition of 2,518 restricted stock units and 9,216 non-qualified stock options as part of compensation on June 10, 2025.

Summary

• Incyte Corporation (INCY) Director Otis W. Brawley reported new equity awards on June 10, 2025.
• Brawley was granted 2,518 shares of common stock in the form of Restricted Stock Units (RSUs).
• These RSUs vest in full on the first anniversary of the grant date, the date of the next regular annual meeting of the Company's stockholders, or upon a change of control, and are settled on a one-for-one basis for common stock.
• Following this grant, Brawley beneficially owns an aggregate of 11,252 shares of common stock, which includes the newly granted RSUs and previously reported unvested restricted stock units.
• Additionally, Brawley was granted 9,216 non-qualified stock options with an exercise price of $70.07 per share.
• These options also vest in full on the first anniversary of the grant date, the date of the next regular annual meeting, or upon a change of control, and are set to expire on June 9, 2035.

Sentiment

Score: 7

Explanation: The document reports standard equity compensation for a director, which is a positive sign of continued alignment between management and shareholder interests, indicating stability and long-term commitment.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests with the long-term performance and shareholder value of Incyte Corporation.
• Equity compensation is a standard practice that incentivizes directors to contribute to the company's sustained growth and success.

Future Outlook

The vesting schedules for the granted Restricted Stock Units and Non-Qualified Stock Options indicate future potential share ownership for Director Brawley, contingent on continued service and/or specific corporate events such as a change of control.

Industry Context

This filing reflects a routine equity compensation award to a director, which is a common practice across the biotechnology and pharmaceutical industries. Such awards are designed to align the interests of company leadership with those of shareholders, promoting long-term value creation.

Comparison to Industry Standards

• Director compensation packages in the biotechnology sector typically include a mix of cash, restricted stock, and stock options. The specific grant sizes for Incyte's director, Otis W. Brawley, would need to be benchmarked against peer companies such as Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), or Gilead Sciences (GILD) to assess if they are within typical ranges for a director at a company of Incyte's market capitalization and stage of development. Without specific peer data, this type of equity award is consistent with general industry practices for incentivizing long-term performance.

Corporate Governance

Related Party Transactions

• The equity awards (Restricted Stock Units and Non-Qualified Stock Options) granted to Director Otis W. Brawley constitute compensation from the company to a related party (an insider). This is a standard, disclosed form of executive and director compensation.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial incentives with the company's long-term performance, potentially benefiting shareholders through increased focus on value creation.

Next Steps

• The granted Restricted Stock Units and Non-Qualified Stock Options will vest according to their specified schedules: on the first anniversary of the grant date, the date of the next regular annual meeting of the Company's stockholders, or upon a change of control.

Key Dates

Recommendation

Keywords

Incyte Corporation, INCY, SEC Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Corporate Governance